Illumina Launches TruSight Oncology 500 to Power Comprehensive, Accurate, Pan-Cancer Tumor Profiling - Seite 2

Pharmaceutical partners and payers are shifting toward deeper, broader sequencing to help predict which patients may benefit from new treatments including immunotherapies, targeted therapies and the many potential combinations. Recently, Bristol-Myers Squibb Company (NYSE: BMY) and Illumina announced a collaboration to develop and globally commercialize companion diagnostics, based on TruSight Oncology 500 content, to support Bristol-Myers Squibb’s oncology portfolio.

“By focusing on our most differentiated oncology products, we can meet the needs of our customers and provide a comprehensive NGS panel that includes all of the known and anticipated biomarkers associated with targeted and immune-based therapies,” said Garret Hampton, Executive Vice President of Clinical Genomics at Illumina. “As we move to bring a future in vitro diagnostic version through regulatory approval, we will be able to set the standard for accurate and reproducible testing. Today’s value in the capability to call for TMB is in line with current research and emerging guidelines, but the promise that TruSight Oncology 500 holds for the future identification of biomarkers, makes it a robust solution for this rapidly evolving field.”

TruSight Oncology 500 offers deep, adaptable, and accessible sequencing power:

• Goes beyond current cancer guidelines and clinical trials – The deep investigational power of TSO 500 covers a large number of genes – alterations that are being used to identify patients for clinical trials – while covering 1.94Mb of the genome to measure TMB.
• Unlocks immunotherapy research – Rigorously developed and accurate TMB and MSI algorithms, with a dedicated tumor-only workflow, while also offering the flexibility to detect a vast majority of known genetic variants, whether it be small variants, gene amplifications, de novo fusions, or splice variants.
• Integrated tumor-only, RNA+DNA workflow: The ability to run RNA and DNA biomarkers into one workflow enables a lab to evaluate all relevant biomarkers at the same time. In addition, being able to run tumor-only workflow enables cost savings for a lab since there is no need to run a normal sample each time.

For additional product and availability information, please visit: www.illumina.com/TruSightOncology500